Brain Tumor-Penetrating Nanoparticle Delivery with MR-Guided Focused Ultrasound
利用 MR 引导聚焦超声进行脑肿瘤穿透纳米颗粒递送
基本信息
- 批准号:8221545
- 负责人:
- 金额:$ 72.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-05-07 至 2017-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsAftercareAnimalsBiodistributionBlood - brain barrier anatomyBlood CirculationBrainBrain NeoplasmsBrain regionCaliberCharacteristicsChargeChemistryClinicClinicalClinical TrialsConfocal MicroscopyContrast MediaConvectionCouplesDataDiffusionDoseDrug ControlsDrug Delivery SystemsDrug DesignDrug EvaluationDrug FormulationsDrug KineticsDrug usageEngineeringEquipmentEssential TremorExtracellular MatrixFamily suidaeFluorescenceFocused Ultrasound TherapyGadoliniumGliadel WafersGlioblastomaHeadHistologicHistologyHousingImageImplantInflammationInjection of therapeutic agentIntravenousKineticsLabelLeadMagnetic ResonanceMagnetic Resonance ImagingMalignant neoplasm of brainMaximum Tolerated DoseMeasuresMetastatic malignant neoplasm to brainMicrobubblesModelingMolecularPaclitaxelPenetrationPharmaceutical PreparationsPolyethylene GlycolsPolystyrenesPositioning AttributePriceRadioRattusResearchSafetySurfaceSurvival RateSystemTechnologyTestingTherapeuticTherapeutic EffectTimeTissuesToxic effectTracerTranslationsTreatment EfficacyTumor TissueUltrasonographyUniversitiesVirginiaaggressive therapybasebiodegradable polymerbrain tissuecancer therapychemotherapydensitydrug distributiondrug efficacygadolinium oxidegliosarcomaimprovedin vivoinnovationnanoparticleneoplastic cellnew technologyparticlepreclinical studypressurerat Ran 2 proteinsafety studysafety testingsuccesstomographytumortumor growth
项目摘要
DESCRIPTION (provided by applicant): Glioblastoma multiforme (GBM), the most common primary brain cancer, has a 5-year survival rate of <12%. GBM treatment is severely limited by the fact that chemotherapeutic drugs reach the brain in very low concentrations due to the blood brain barrier (BBB). Current strategies to circumvent the BBB (i.e. Gliadel wafers and convection enhanced delivery) are invasive and lead to only moderate improvements in survival. Clearly, less-invasive strategies that provide sustained and well-dispersed drug delivery to brain tumors are needed. To address this need, we propose an innovative image guided drug-delivery approach that couples magnetic resonance (MR)-targeted BBB opening via focused ultrasound (FUS) and microbubbles (MBs) with drug-loaded nanoparticles that have been engineered with extremely dense polyethylene glycol (PEG) coatings to rapidly penetrate brain tissue (i.e. "brain penetrating nanoparticles" or BPNs). We hypothesize that this approach will improve brain cancer treatment by enhancing drug delivery across the BBB to FUS-targeted tumors, providing sustained drug delivery deep within tumors, and minimizing systemic side effects. We will test this hypothesis with 4 aims. In Aim 1, we will optimize BPN size and surface chemistry for brain tumor penetration and long circulation time. Tracer BPNs will be used to determine the nanoparticle size range and surface chemistry required to produce BPNs with controlled particle penetration depths in freshly obtained brain tumors ex vivo. Subsequently, BPNs with these optimal characteristics will be generated from biodegradable polymers and tested. In Aim 2, running in parallel with Aim 1, we will determine FUS pressure thresholds for safe and reversible MR-guided BBB opening to gadolinium in intracranial 9L rat brain tumors as a function of MB diameter. Then, FUS pressure thresholds will be used as a basis for determining optimal FUS and MB parameters for delivering the most promising BPN formulation from Aim 1 to brain tumors. These FUS and MB parameters will be carried to Aim 3, wherein we will evaluate whole-body and brain biodistributions of biodegradable BPNs via Fluorescence Molecular Tomography (FMT). BPN dispersion into the brain after delivery across the BBB will be further analyzed in detail using confocal microscopy. Brain tissue inflammation, which is expected to be negligible or absent, will be assessed histologically. In Aim 4, we will first determine the maximum tolerated dose (MTD) of paclitaxel-loaded BPNs, followed by an evaluation of drug pharmacokinetics (PK). Finally, we will determine the overall efficacy of drug-loaded BPN delivery with MR- guided FUS and MBs to invasive brain tumors by measuring reduced tumor growth and enhanced animal survival after treatment. If these pre-clinical studies proceed as expected, we are well-positioned for translation to the clinic. Our next step would be to test the safety of the MR-guided BPN delivery approach in large animals (pig) using the University of Virginia's clinical Insightec Exablate system, followed by the initiation of a clinical trial.
PUBLIC HEALTH RELEVANCE: Chemotherapy is often ineffective when treating brain tumors because the interface between the bloodstream and the brain, which is called the blood-brain barrier, is not permeable to drugs in the bloodstream. We are testing the ability of a new technology, which uses MR imaging and specialized ultrasound equipment to open the blood-brain barrier around brain tumors, to permit the delivery of specially designed drug-carrying nanoparticles for improved brain cancer treatment.
描述(申请人提供):多形性胶质母细胞瘤(GBM)是最常见的原发脑癌,5年生存率为12%。由于血脑屏障(BBB)的作用,化疗药物以极低的浓度进入大脑,这一事实严重限制了GBM的治疗。目前规避BBB的策略(即格利亚德尔晶片和对流增强输送)是侵入性的,只能适度提高存活率。显然,需要侵入性较小的策略,为脑瘤提供持续和分散的药物输送。为了满足这一需求,我们提出了一种创新的图像引导药物输送方法,通过聚焦超声(FUS)和微泡(MBS)将磁共振(MR)靶向的BBB开口与载药纳米颗粒相结合,这些纳米颗粒已经被设计成具有极高密度的聚乙二醇(PEG)涂层,以快速穿透脑组织(即“脑穿透纳米颗粒”或BPN)。我们假设,这种方法将通过增强跨血脑屏障向FUS靶向肿瘤的药物输送,在肿瘤内部提供持续的药物输送,并将全身副作用降至最低,从而改善脑癌的治疗。我们将用四个目标来检验这一假设。在目标1中,我们将优化BPN的大小和表面化学,以实现脑肿瘤的穿透和长循环时间。示踪剂BPN将被用来确定在体外新获得的脑瘤中生产具有可控颗粒渗透深度的BPN所需的纳米颗粒大小范围和表面化学。随后,将从可生物降解的聚合物中生成具有这些最佳特性的BPN并进行测试。在与目标1平行运行的目标2中,我们将确定安全且可逆的MR引导血脑屏障对9L大鼠颅内肿瘤开放的FUS压力阈值,作为MB直径的函数。然后,FUS压力阈值将被用作确定最佳FUS和MB参数的基础,以将最有希望的BPN配方从AIM 1输送到脑肿瘤。这些FUS和MB参数将被带到目标3,在那里我们将通过荧光分子断层成像(FMT)来评估可生物降解的BPN的全身和脑内的生物分布。BPN在跨血脑屏障传递后进入大脑的分散将使用共聚焦显微镜进一步详细分析。脑组织炎症预计可以忽略不计或不存在,将进行组织学评估。在目标4中,我们将首先确定紫杉醇BPN的最大耐受量(MTD),然后评估药物的药代动力学(PK)。最后,我们将通过测量治疗后肿瘤生长减少和提高动物存活率来确定MR引导下FUS和MBS载药BPN对侵袭性脑肿瘤的整体疗效。如果这些临床前研究如预期那样进行,我们就可以很好地将其转移到临床上。我们的下一步将是使用弗吉尼亚大学的临床InSightec ExAblate系统在大型动物(猪)中测试MR引导的BPN传递方法的安全性,然后启动临床试验。
与公共卫生相关:在治疗脑肿瘤时,化疗往往无效,因为血液和大脑之间的界面,即所谓的血脑屏障,对血液中的药物不具渗透性。我们正在测试一项新技术的能力,该技术使用磁共振成像和专门的超声波设备来打开脑瘤周围的血脑屏障,从而允许输送专门设计的携带药物的纳米颗粒来改善脑癌的治疗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(6)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Justin S. Hanes其他文献
Justin S. Hanes的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Justin S. Hanes', 18)}}的其他基金
Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas
聚焦超声预处理增强纳米颗粒在浸润性神经胶质瘤中的渗透
- 批准号:
10375573 - 财政年份:2021
- 资助金额:
$ 72.13万 - 项目类别:
Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas
聚焦超声预处理增强纳米颗粒在浸润性神经胶质瘤中的渗透
- 批准号:
10210648 - 财政年份:2021
- 资助金额:
$ 72.13万 - 项目类别:
Focused ultrasound pre-conditioning for augmented nanoparticle penetration in infiltrative gliomas
聚焦超声预处理增强纳米颗粒在浸润性神经胶质瘤中的渗透
- 批准号:
10541232 - 财政年份:2021
- 资助金额:
$ 72.13万 - 项目类别:
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
脑部穿透性 DNA 纳米颗粒靶向递送至脑肿瘤
- 批准号:
9083426 - 财政年份:2016
- 资助金额:
$ 72.13万 - 项目类别:
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
脑部穿透性 DNA 纳米颗粒靶向递送至脑肿瘤
- 批准号:
9260870 - 财政年份:2016
- 资助金额:
$ 72.13万 - 项目类别:
Targeted Delivery of Brain Penetrating DNA Nanoparticles to Brain Tumors
脑部穿透性 DNA 纳米颗粒靶向递送至脑肿瘤
- 批准号:
9891031 - 财政年份:2016
- 资助金额:
$ 72.13万 - 项目类别:
Biodegradable Mucus Penetrating DNA Nanoparticle for Gene Therapy of CF
用于 CF 基因治疗的可生物降解粘液穿透 DNA 纳米颗粒
- 批准号:
8863900 - 财政年份:2015
- 资助金额:
$ 72.13万 - 项目类别:
Mucus Microstructure and Osmotic Pressure: Biomarkers for CB in COPD
粘液微观结构和渗透压:COPD 中 CB 的生物标志物
- 批准号:
8852864 - 财政年份:2015
- 资助金额:
$ 72.13万 - 项目类别:
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy
谷氨酰胺酶抑制剂药物的发现和基于纳米颗粒的胰腺癌治疗递送
- 批准号:
9188044 - 财政年份:2015
- 资助金额:
$ 72.13万 - 项目类别:
Glutaminase Inhibitor Drug Discovery and Nanoparticle-Based Delivery for Pancreatic Cancer Therapy
谷氨酰胺酶抑制剂药物的发现和基于纳米颗粒的胰腺癌治疗递送
- 批准号:
9028315 - 财政年份:2015
- 资助金额:
$ 72.13万 - 项目类别:
相似海外基金
Unraveling Adverse Effects of Checkpoint Inhibitors Using iPSC-derived Cardiac Organoids
使用 iPSC 衍生的心脏类器官揭示检查点抑制剂的副作用
- 批准号:
10591918 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Optimization of mRNA-LNP vaccine for attenuating adverse effects and analysis of mechanism behind adverse effects
mRNA-LNP疫苗减轻不良反应的优化及不良反应机制分析
- 批准号:
23K15383 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of adverse effects of combined exposure to low-dose chemicals in the living environment on allergic diseases and attempts to reduce allergy
阐明生活环境中低剂量化学品联合暴露对过敏性疾病的不良影响并尝试减少过敏
- 批准号:
23H03556 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Green tea-based nano-enhancer as an adjuvant for amplified efficacy and reduced adverse effects in anti-angiogenic drug treatments
基于绿茶的纳米增强剂作为抗血管生成药物治疗中增强疗效并减少不良反应的佐剂
- 批准号:
23K17212 - 财政年份:2023
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Effects of Tobacco Heating System on the male reproductive function and towards to the reduce of the adverse effects.
烟草加热系统对男性生殖功能的影响以及减少不利影响。
- 批准号:
22H03519 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Mitigating the Adverse Effects of Ultrafines in Pressure Filtration of Oil Sands Tailings
减轻油砂尾矿压力过滤中超细粉的不利影响
- 批准号:
563657-2021 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
Alliance Grants
1/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
1/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10521849 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
4/4-Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
4/4-破译ECT结果和不良反应的机制(DECODE)
- 批准号:
10671022 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
2/4 Deciphering Mechanisms of ECT Outcomes and Adverse Effects (DECODE)
2/4 ECT 结果和不良反应的破译机制(DECODE)
- 批准号:
10670918 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
Downsides of downhill: The adverse effects of head vibration associated with downhill mountain biking on visuomotor and cognitive function
速降的缺点:与速降山地自行车相关的头部振动对视觉运动和认知功能的不利影响
- 批准号:
2706416 - 财政年份:2022
- 资助金额:
$ 72.13万 - 项目类别:
Studentship